Author: OurCrowd

[BlueNalu in Business Wire] BlueNalu strengthens strategic partnerships with prominent seafood companies in the APAC region

Oct 3, 2023 |

SAN DIEGO–(BUSINESS WIRE)–BlueNalu, a global leader in the development of cell-cultured seafood, announced today the extension and enhancement of its strategic partnerships with three multinational seafood industry leaders headquartered in the Asia-Pacific (APAC) region. These partnerships will support BlueNalu’s planned introduction of cell-cultured seafood in a number of APAC nations over the coming years, by fostering market insights, understanding regulatory requirements, and developing go-to-market strategies. Read...

Read More

[AEYE Health in PR Newswire] AEYE Health makes Its one-image-per-eye diabetic eye exam even faster by cutting processing time to under 5 seconds

Oct 3, 2023 |

NEW YORK, Oct. 3, 2023 /PRNewswire/ — AEYE Health, a leading provider of AI-based diabetic retinopathy (DR) screening solution, today announced that it has significantly reduced the processing time for its best-in-class AEYE-DS diabetic retinopathy screening system to under 5 seconds. This improvement is the result of smarter utilization of computing resources that accelerate the execution of the AI algorithms. Read more...

Read More

[OncoHost in PR Newswire] OncoHost’s PROphet® Platform to support Henlius US-Based Phase III Trial for patients with extensive-stage small cell lung cancer

Oct 3, 2023 |

BINYAMINA, Israel , Oct. 3, 2023 /PRNewswire/ — OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a collaboration with Hengenix Biotech, Inc. (Henlius USA), affiliated with Shanghai Henlius Biotech, Inc., a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Henlius USA will utilize OncoHost’s PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial (NCT05468489). The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin – etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Read...

Read More